Shift from broad spectrum generic oncology drugs such as traditional injectable cytotoxic drugs to a more precise and targeted small molecule can be observed in the injectable cytotoxic drugs industry. Injectable cytotoxic drugs are increasingly being used in combination with targeted therapies to enhance treatment efficacy and overcome resistance mechanisms, particularly in cancers with actionable mutations or biomarkers.
Furthermore, use of natural compounds derived from plants and marine organisms, as a potent sources for developing anticancer agents with cytotoxic properties such as Artemisinin has driven the significant investments from pharmaceutical companies. For instance, according to an article published by National Center for Biotechnology Information, by the end of 2022, there were 17 marine derived drugs approved for clinical use, out of these, about 71% were approved for the treatment of various cancer types.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The global market size for injectable cytotoxic drugs was valued at USD 9.7 billion in 2023 and is anticipated to showcase 5.8% CAGR from 2024 – 2032, driven by the increasing incidence of cancer and rheumatoid arthritis.
The antimetabolites drug class segment of the injectable cytotoxic drugs market held 44.2% share in 2023 and will expand rapidly through 2032, attributed to their wide use in anti-cancer therapies.
North America market accounted for 42.2% share in 2023 and is predicted to reach USD 6.6 billion by 2032, driven by the presence of large number of pharmaceutical manufacturers offering advanced treatment options for cancer treatment.
Abbvie Inc, Accord Healthcare, Amgen, Inc.,Baxter International Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Fresenius Kabi AG among others.